Project Grant HT94252510243
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $1,178,136.00 to The Trustees of the University of Pennsylvania (Clinical Practices of the University of Pennsylvania) to conduct research on exploiting the absence of TP53 mutations in epithelial ovarian cancer using next-generation p53-stabilizing agents. The research project aims to develop innovative therapeutic approaches for this type of...
The Department of the Army Medical Command awarded a $2,843,750 Project Grant to The Trustees of the University of Pennsylvania under the Military Medical Research and Development program (CFDA 12.420). The grant supports the Department of Defense Omics Consortium to Study the Origins of Ovarian Cancer (DOCSOOC) from August 15, 2022 to August 14, 2026. The Consortium will develop a pathology resource for pan-omic studies of tubal precursors to ovarian cancer. It will facilitate communication and...
The University of Pittsburgh was awarded a $873,419 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to investigate stromal drivers of ovarian cancer initiation. The University will examine medical solutions for ovarian cancer through basic, applied, and advanced biomedical research efforts. A sub-award of $100,000 was also provided to The Johns Hopkins University to support this research project, which aims...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...
This federal Project Grant award in the amount of $1,439,093.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of New Mexico Health Sciences Center (UNM HSC). The grant will support advancing clinical research on ovarian cancer over a performance period from June 1, 2024 to May 31, 2028. As part of this award, UNM HSC will leverage its expertise in cancer research, genomics, and clinical trials to conduct...
This federal Project Grant award, valued at $1,555,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the University of Wisconsin System's research initiative to develop population modeling to optimize equitable ovarian cancer outcomes. The project aims to transform healthcare for military service members and the broader public by advancing innovative research on disease prevention, diagnosis, and...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
This federal Project Grant award in the amount of $1,605,638.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a private research university and academic medical center. The grant funding supports research aimed at developing new methods for immune targeting of dormant tumor...
This $427,109 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at the University of Oklahoma Health Sciences Center to investigate targeting DCLK1-mediated glutamine addiction in chemoresistant ovarian cancer metastases. The two-year project, running from May 2025 to May 2027, aims to develop innovative strategies for preventing and treating advanced ovarian cancer by exploring the role of a...